Cargando…
The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis
Non-small cell lung cancer (NSCLC) remains a problem worldwide due to its rapid progression and low rate of response to treatment. The heterogeneity of these tumors observed in histopathology exam but also in the mutational status and gene expression pattern makes this malignancy difficult to treat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604406/ https://www.ncbi.nlm.nih.gov/pubmed/33194579 http://dx.doi.org/10.3389/fonc.2020.516850 |
_version_ | 1783604138391633920 |
---|---|
author | Pop-Bica, Cecilia Pintea, Sebastian Magdo, Lorand Cojocneanu, Roxana Gulei, Diana Ferracin, Manuela Berindan-Neagoe, Ioana |
author_facet | Pop-Bica, Cecilia Pintea, Sebastian Magdo, Lorand Cojocneanu, Roxana Gulei, Diana Ferracin, Manuela Berindan-Neagoe, Ioana |
author_sort | Pop-Bica, Cecilia |
collection | PubMed |
description | Non-small cell lung cancer (NSCLC) remains a problem worldwide due to its rapid progression and low rate of response to treatment. The heterogeneity of these tumors observed in histopathology exam but also in the mutational status and gene expression pattern makes this malignancy difficult to treat in clinic. The present study investigated the effect of miR-21 and let-7 family members as prognostic biomarkers in NSCLC patients based on the results published in different studies regarding this subject until March 2019. The analysis revealed that these two transcripts are steady biomarkers for prediction of patient outcome or survival. Upregulated expression of miR-21 is associated with poor outcome of patients with NSCLC [HR = 1.87, 95% CI = (1.41, 2.47), p < 0.001]. The analysis regarding let-7 family, specifically let-7a/b/e/f, revealed that downregulated expression of these transcripts predicts poor outcome for NSCLC patients [HR = 2.61, 95% CI = (1.58, 4.30), p < 0.001]. Besides, the reliability of these microRNAs is reflected in the fact that their prognostic significance is constant given the different sample types (tissue, FFPE tissue, serum, serum/plasma or exosomes) used in the selected studies. |
format | Online Article Text |
id | pubmed-7604406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76044062020-11-13 The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis Pop-Bica, Cecilia Pintea, Sebastian Magdo, Lorand Cojocneanu, Roxana Gulei, Diana Ferracin, Manuela Berindan-Neagoe, Ioana Front Oncol Oncology Non-small cell lung cancer (NSCLC) remains a problem worldwide due to its rapid progression and low rate of response to treatment. The heterogeneity of these tumors observed in histopathology exam but also in the mutational status and gene expression pattern makes this malignancy difficult to treat in clinic. The present study investigated the effect of miR-21 and let-7 family members as prognostic biomarkers in NSCLC patients based on the results published in different studies regarding this subject until March 2019. The analysis revealed that these two transcripts are steady biomarkers for prediction of patient outcome or survival. Upregulated expression of miR-21 is associated with poor outcome of patients with NSCLC [HR = 1.87, 95% CI = (1.41, 2.47), p < 0.001]. The analysis regarding let-7 family, specifically let-7a/b/e/f, revealed that downregulated expression of these transcripts predicts poor outcome for NSCLC patients [HR = 2.61, 95% CI = (1.58, 4.30), p < 0.001]. Besides, the reliability of these microRNAs is reflected in the fact that their prognostic significance is constant given the different sample types (tissue, FFPE tissue, serum, serum/plasma or exosomes) used in the selected studies. Frontiers Media S.A. 2020-10-19 /pmc/articles/PMC7604406/ /pubmed/33194579 http://dx.doi.org/10.3389/fonc.2020.516850 Text en Copyright © 2020 Pop-Bica, Pintea, Magdo, Cojocneanu, Gulei, Ferracin and Berindan-Neagoe. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Pop-Bica, Cecilia Pintea, Sebastian Magdo, Lorand Cojocneanu, Roxana Gulei, Diana Ferracin, Manuela Berindan-Neagoe, Ioana The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis |
title | The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis |
title_full | The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis |
title_fullStr | The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis |
title_full_unstemmed | The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis |
title_short | The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis |
title_sort | clinical utility of mir-21 and let-7 in non-small cell lung cancer (nsclc). a systematic review and meta-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604406/ https://www.ncbi.nlm.nih.gov/pubmed/33194579 http://dx.doi.org/10.3389/fonc.2020.516850 |
work_keys_str_mv | AT popbicacecilia theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT pinteasebastian theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT magdolorand theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT cojocneanuroxana theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT guleidiana theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT ferracinmanuela theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT berindanneagoeioana theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT popbicacecilia clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT pinteasebastian clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT magdolorand clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT cojocneanuroxana clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT guleidiana clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT ferracinmanuela clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis AT berindanneagoeioana clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis |